Retina Society 2018: AMD Session Part II
Yoshihiro Yonekawa, MD Mass Eye & Ear / Boston Children’s RETINA Roundup Co-Editor We continue coverage of the 2018 Retina Society annual meeting in San Francisco. Yesterday we presented summaries…
Category: AMD
Retina Society 2018: AMD Part I (Including First-Time Presentation of Genentech’s Bispecific Anti-VEGF/Ang2 Agent for Neovascular AMD)
Yoshihiro Yonekawa, MD Mass Eye & Ear / Boston Children’s RETINA Roundup Co-Editor The age-related macular degeneration (AMD) session at Retina Society is always jam-packed. Patients with AMD comprise a…
Not All is Dry with Dry AMD
And now…finally…some good news in dry AMD! Geographic atrophy (GA) remains a significant unmet need that has been met with great attention by investigators and industry. However, until now, all…
Lampalizumab Does Not Meet Primary Endpoint
Genentech reported yesterday that lampalizumab did not meet the primary endpoint in SPECTRI, one of the two parallel Phase III clinical trials investigating lampalizumab injections for the treatment of geographic…
HAWK/HARRIER: Coming in for a Landing
In June, Novartis announced results from HAWK and HARRIER, two phase III clinical trials comparing brolocizumab (formerly RTH258) to aflibercept for the treatment of wet AMD. The primary endpoints were…
ASRS 2017 Monday (Day 4): Neovascular AMD
Day 4 of the ASRS annual meeting has provided us with even more clinically relevant information regarding neovascular age-related macular degeneration (nvAMD) and retinal detachments (RDs). Both Geoffrey Emerson and…
The LADDER Trial
Genentech is again pursuing novel and creative ways to improve patient outcomes by testing long-term anti-VEGF delivery in the LADDER trial (Study of the Efficacy and Safety of the Ranibizumab…